Ruti Aga Handed Six-Year Ban Over Forged Prescription as AIU Draws a Hard Line

Ethiopian distance runner and 2026 Tokyo Marathon champion Ruti Aga has been banned for six years by the Athletics Integrity Unit (AIU). The sanction is a composite of two separate violations: the presence of a prohibited substance in a sample taken after she won a half marathon in China in March, and a forged prescription submitted to explain that substance, which the AIU has classified as tampering. According to the AIU statement issued on Thursday, the ban runs from 10 September—the same date her provisional suspension took effect. The arithmetic is the story. Two years for the presence violation, four years for tampering arising from a misleading fabricated document and statements made during the investigation. Two plus four equals six. That total also tells us the panel rejected the no-significant-fault mitigation that could have reduced the presence sanction. In other words, the athlete's damage came not from the medication itself but from the method used to conceal it. The structure is standard rather than exceptional: both components sit within the fixed ranges of the World Anti-Doping Code. The technical point most reports got wrong: methylprednisolone is not a prohibited anabolic steroid. It is a glucocorticoid, listed under class S9 of the WADA Prohibited List, not class S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. An injection administered out-of-competition is entirely legal; it becomes a violation only when residues are present in-competition. The case therefore hinges on route of administration and timing relative to the race, not on steroid use. That distinction is legally decisive because it opened a legitimate defence pathway. In road racing the testing window opens at 23:59 the day before the race, which is why an injection given days earlier can still be caught. Aga's defence cited a knee injury. Intra-articular or peri-articular methylprednisolone for knee inflammation is routine sports medicine in distance runners. The explanation is medically plausible—and that plausibility is precisely what made the forgery decisive. Genuine treatment with genuine records would have been defended with those records; there would have been no need to manufacture paper. A properly managed athlete would either hold or apply for a Therapeutic Use Exemption, or observe the route-specific washout period. Neither appears to have happened. According to the AIU, the prescription was issued in the name of a clinic that does not exist; the person presented as the doctor was a family member with no medical registration; and that person claimed to have used an old prescription pad from a former workplace, which the clinic explicitly disowned. That is three independent verification failures. In sports law the family connection is an aggravating fact, not a mitigating one. Notably, the four-year sanction arises from an interview as well as a document—statements made under questioning formed part of the basis. Language and translation conditions in such interviews are a recurring point of contention. Regardless, this decision rests on both the paperwork and the account given around it. Clarity is needed on the March race. Aga won a half marathon in China, but no mark, split or field quality is disclosed, so no performance judgement is possible. The only performance-relevant fact is that she won, implying a World Athletics Label-tier event with in-competition testing. Her result and prize money from that race are very likely to be annulled, along with ranking points accrued after that date, though the statement does not spell out the scope. The career arithmetic is brutal. Aga is 32. She won Tokyo in 2026 and finished second at three World Marathon Majors. Her best-known mark, roughly 2:18:34 at Berlin 2026, comes from independent records and is not in the AIU statement. A six-year ban removes her from the 2028 Olympic cycle entirely, and a return would come at around 38—an age at which, given Ethiopian women's marathon depth, national selection is implausible. Functionally, this is a lifetime ban at elite level. What survives is the 2026 Tokyo title and the three Major runner-up finishes, absent any finding of earlier use; the violation is anchored to a later race, so prior results are not automatically void. But her standing is now bifurcated: the sporting record remains, the commercially viable profile does not. An appeal is live but low-value. A CAS appeal is typically available within about 21 days of the reasoned decision, but a document-based forgery finding is hard to overturn. Criminal exposure at national level for document forgery cannot be excluded either, and sits outside AIU jurisdiction. Backdating the ban to 10 September is a procedural benefit, not a reduction—provisional suspension time simply counts against the total. The counterfactual matters. With genuine records and a demonstrated route and timing explanation, the presence charge could have been argued at the reduced end and no tampering charge would have arisen at all. In the best case—a TUE-consistent treatment plan and correct washout timing—there would have been no case. Four of the six years exist because the paperwork was fake. This is not only an individual case. In East African road running the role of agents, managers and informal medical networks is a recurring question. Injured marathoners face pressure to protect appearance-fee income, glucocorticoid injections are the cheapest available tool for masking pain, and a credentialed team physician is often absent. The forged prescription is downstream of that governance gap, and a chronic knee problem would suggest a repeated pattern of informal treatment. Whether an agent advised or accepted the document is not stated; the AIU names only the family member. No statement from the Ethiopian federation has been quoted. The wider shift is that enforcement is moving from detection to document verification. China's label-race circuit—large appearance-fee budgets, deep East African elite fields, AIU testing—is now a high-scrutiny zone. There will also be a debate about proportionality: six years for a substance with no proven endurance benefit will be cited both as evidence of AIU rigour and as evidence of disproportionate enforcement. Aga's case will remain the clearest illustration of the arithmetic: two years for the drug, four for hiding it.